Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects

The healthy male subjects will be screened no more than 14 days before the dose (D-14 through D-3) and admitted to the clinical research center 2 days before the dose (D-2). The subjects will receive a single oral administration of approximately 50 mg/100 µCi [14C]X842 suspension orally on an empty stomach on day 1.

Urine and feces samples will be all collected from the subjects before and at specified intervals between 0 and 312 hours after taking the drug and blood samples will be collected at specified time points between 0 and 216 hours before and after taking the drug.

Inclusion criteria

• Healthy adult males;
• Age: 18 to 45 years (inclusive)
• Body weight: ≥50 kg with body mass index (BMI) between 19.0 and 26.0 kg/m² (inclusive);
• Fully understand the trial objectives, requirements, procedures, and potential adverse reactions; voluntarily participate; able to complete the study per protocol and comply with regulations; informed consent obtained in compliance with GCP;
• The subjects were able to communicate well with the researchers and complete the trial in accordance with the provisions of the protocol.

Exclusion criteria

• Auxiliary Examinations:

• Subjects with abnormal and clinically significant findings in Physical examination, Vital signs, Laboratory tests (including hematology, blood biochemistry, coagulation, urinalysis, fecal occult blood),Thyroid function, 12-lead ECG, Anteroposterior chest X-ray, Abdominal ultrasound, and/or other clinically relevant investigations;
• Subjects testing positive for: Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV-Ab), Human immunodeficiency virus antibody (HIV-Ab),Treponema pallidum antibody (syphilis screening);

-Medication History:

• Subjects with use of any medications known to inhibit or induce hepatic drug-metabolizing enzymes within 30 days prior to screening；
• Subjects with use of any prescription medications, over-the-counter drugs, Chinese herbal medicines, or dietary supplements (e.g., vitamins, calcium) within 14 days prior to screening;

-Disease and Surgical History

• History of any clinically significant disease or condition that the investigator deems may affect the trial results, including but not limited to diseases of the circulatory, respiratory, endocrine, nervous, digestive, urinary systems, or blood, immune, psychiatric, and metabolic disorders;
• History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsade de pointes, ventricular tachycardia, atrioventricular block, long QT syndrome, or family history thereof (as evidenced by genetic confirmation or sudden cardiac death of close relatives at a young age);
• Major surgery within 6 months prior to screening, or incompletely healed surgical wounds; Major surgery includes, but is not limited to, any procedure with significant bleeding risk, prolonged general anesthesia, open biopsy, or significant traumatic injury;
• Subjects have prone to allergies, such as a known history of hypersensitivity to two or more substances; or individuals deemed by the investigator as potentially allergic to the trial drug or its excipients;
• Subjects with regular/ongoing hematochezia, irritable bowel syndrome, inflammatory bowel disease;

-life style

• Subjects with habitual constipation or diarrhea;
• Subjects who has the history of alcoholism or regular alcohol consumption within 6 months prior to screening, defined as consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine), and inability to abstain during the trial period; or a breath alcohol test result ≥ 0 mg/dL at screening;
• Subjects who have smoked more than 5 cigarettes per day or habitually using nicotine-containing products within 3 months prior to screening, or who are unable to stop using any tobacco products during the trial;
• Subjects who have a history of drug abuse within three months prior to the screening period or whose urine test for prohibited drugs (morphine, methamphetamine, ketamine, dimethylene dioxyethanol, tetrahydrocannabinic acid) is positive during the screening;
• Subjects who has habitually consumption of grapefruit juice or excessive amounts of tea, coffee and/or caffeinated beverages and are unable to quit during the trial period;
• Subjects who are exposed to radioactive work conditions for a long time, or have significant radiation exposure (≥ 2 chest/abdominal CTs, or ≥ 3 other types of X-ray examinations) within 1 year before the first dose, or have participated in a radiopharmaceutical labeled trial;
• Subjects with a history of blood or needle phobia, and those who have difficulty in blood collection or cannot tolerate venipuncture blood collection;
• Subjects have participated in any other clinical trial (including trials of investigational drugs or medical devices, etc.) within 3 months prior to the screening period.
• Subjects who have received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
• subjects who plan to conceive or donate sperm during the trial period or within 1 year after trial completion, or those who do not agree that the subject and their partner must use highly effective contraception during the trial period and for 1 year after trial completion;
• Subjects who have lost blood or donated blood (200mL), or received blood transfusions within 3 month before the screening period.
• Subjects who are unsuitable for the study participation for other reasons at the discretion of the investigator;